Results 31 to 40 of about 185,181 (328)
Pharmaceutics, 2022 Warfarin is extensively used for venous thromboembolism and other coagulopathies. In clinical settings, warfarin is administered as a mixture of S- and R-warfarin, and both enantiomers are metabolized by multiple cytochrome P450 enzymes into many ...
Shasha Jin +6 more
doaj +1 more source
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Blood, 2018 Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholipid ...
V. Pengo +21 more
semanticscholar +1 more source
Thrombosis Journal, 2008 Introduction Atrial fibrillation affects an estimated 2.5 million Americans and incurs an average annual stroke risk of 4.5% per year. Despite warfarin reducing stroke risk by approximately 66%, prior studies show warfarin usage rates to be about 50 ...
Cavalcante Joao +5 more
doaj +1 more source
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
New England Journal of Medicine, 2009 BACKGROUND The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism.
S. Schulman +8 more
semanticscholar +1 more source
JAMA Network Open, 2020 Key Points Question What is the role of warfarin in preventing ischemic strokes in patients with atrial fibrillation and end-stage renal disease? Findings This meta-analysis found that, although the current literature is only observational, warfarin use ...
M. Randhawa +6 more
semanticscholar +1 more source
Bleeding with direct oral anticoagulants vs warfarin: clinical experience. [PDF]
, 2016 The risk of bleeding in the setting of anticoagulant therapy continues to be re-evaluated following the introduction of a new generation of direct oral anticoagulants (DOACs).
Eikelboom, John, Merli, Geno J.
core +2 more sources
High clearance of (S)‐warfarin in a warfarin‐resistant subject. [PDF]
British Journal of Clinical Pharmacology, 1993 A 30 year old black male required a 60 mg daily dose of warfarin to elicit a therapeutic anticoagulant response (normal warfarin dose 2.5‐ 10 mg day‐1; maximum 15 mg day‐1). Hereditary warfarin resistance was suspected after compliance, diet, concurrent medication and any gastrointestinal disorder were eliminated as contributory causes. The disposition
AA Trowbridge +6 more
openaire +3 more sources
INTERACTIONS OF WARFARIN [PDF]
Biomedical Papers, 2001 In this article, the author reviews and updates the basis of interactions with warfarin, illustrated with appropriate examples. The interactions with drugs, medicinal herbs and foods are summarised.
openaire +3 more sources
Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range [PDF]
, 2016 BACKGROUND: The benefits and harms of oral anticoagulation (OAC) therapy in patients with only one stroke risk factor (i.e. CHA2DS2-VASc= 1 in males, or 2 in females) has been subject of debate.
Lip, Gregory Y. H., Proietti, Marco
core +2 more sources
Warfarin Pharmacogenetics [PDF]
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008 Significant interest in the pharmacogenetics of warfarin therapy has been triggered with the recent package insert update that highlights the potential role of pharmacogenetics in improving the safety and effectiveness of warfarin. We review the evidence of the influence of the two key genes of interest, the cytochrome P450 2C9 gene, CYP2C9, and the ...
Nita A, Limdi, David L, Veenstra
openaire +2 more sources